TEVA(TEVA) GlobeNewswire·2025-03-31 17:00Core Insights - Teva Pharmaceuticals presented a survey study on patient and healthcare professional attitudes towards TEV-'749, a long-acting injectable formulation of olanzapine, at the 2025 Congress of the Schizophrenia International Research Society, showing high satisfaction rates among patients and healthcare providers [1][2][4] Group 1: Survey Findings - Over 92% of schizophrenia patients reported satisfaction with TEV-'749's initiation regimen, dosing schedule, and trial medication [4][12] - 87% of nurses and 72% of physicians expressed satisfaction with TEV-'749 [1][12] - A significant preference for subcutaneous (78.6%) over intramuscular injection (21.4%) was noted among patients, with needle size being a primary factor [5] Group 2: Clinical Context - TEV-'749 is being evaluated in the Phase 3 SOLARIS trial, which aims to assess its efficacy, safety, and tolerability as a long-acting injectable for schizophrenia [11][9] - The drug leverages SteadyTeq™, a proprietary technology for controlled release, which may mitigate the risk of Post-Injection Delirium/Sedation Syndrome (PDSS) associated with current treatments [9][2] Group 3: Healthcare Professional Insights - Healthcare professionals indicated that the post-injection monitoring period could present barriers to treatment, with over 90% of physicians and more than 66% of nurses acknowledging potential challenges [5][12] - A majority of participants preferred a simpler initiation regimen requiring only one injection, with 72.9% of patients and 90.9% of physicians favoring this approach [5][12] Group 4: Broader Implications - Teva's commitment to advancing treatment for schizophrenia is underscored by the positive feedback from the survey, which highlights the importance of patient and provider perspectives in drug development [2][4] - The findings from the survey and ongoing trials may influence future treatment protocols and patient adherence strategies in schizophrenia management [3][4]